But Patel et al. found that in two different pancreatic duct adenocarcinoma models (pancreatic tumor models driven by mutant Kras and B16 melanoma model), RIPK1 inhibitors did not slow tumor growth, and RIPK1 inactivation did not lead to macrophage reprogramming and/or STAT1 activation (Patel et al., 2020). This evidence concerns the gene RIPK1 and pancreatic ductal adenocarcinoma.